Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 89 results for statins

  1. Diabetes: T1DM and statins (IND166)

    This indicator covers the percentage of patients with type 1 diabetes who are aged over 40 years currently treated with a statin. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM142

  2. What are the long-term effects of statin therapy on sub-clinical atherosclerosis in children with FH who are treated with statin therapy?

    are the long-term effects of statin therapy on sub-clinical atherosclerosis in children with FH who are treated with statin...

  3. Peripheral arterial disease: diagnosis and management (CG147)

    This guideline covers diagnosing and managing peripheral arterial disease (PAD) in people aged 18 and over. Rapid changes in diagnostic methods, endovascular treatments and vascular services associated with new specialties in surgery and interventional radiology have resulted in considerable uncertainty and variation in practice. This guideline aims to resolve that uncertainty and variation.

  4. Diabetes: statins for secondary prevention of CVD (IND184)

    This indicator covers the percentage of patients with diabetes and a history of cardiovascular disease (excluding a history of haemorrhagic stroke) who are currently treated with a statin. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM163

  5. Diabetes: statins for primary prevention of CVD (T2DM and 10% risk) (IND182)

    This indicator covers the percentage of patients with a diagnosis of type 2 diabetes and a recorded cardiovascular disease risk assessment score of 10% or more (without moderate or severe frailty), who are currently treated with a statin (unless there is a contraindication or statin therapy is declined). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM161

  6. What is the effectiveness of statin therapy in older people?

    Recommendation ID CG181/3 Question What is the effectiveness of statin therapy in older people? Any explanatory notes(if applicable)

  7. Cardiovascular disease prevention: statins for people newly diagnosed with hypertension or T2DM (IND162)

    This indicator covers, in patients aged between 25 and 84 years, with a new diagnosis of hypertension or type 2 diabetes recorded in the preceding 12 months (excluding those with pre-existing cardiovascular disease, chronic kidney disease, familial hypercholesterolaemia or type 1 diabetes), who have a recorded cardiovascular risk assessment score of more than 20% in the preceding 12 months, the percentage who are currently treated with statins (unless there is a contraindication). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM133

  8. What is the effectivness of statin treatment in older people?

    Recommendation ID NG238//2 Question What is the effectivness of statin treatment in older people? Any explanatory notes(if applicable)

  9. Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)

    This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.

  10. Diabetes: statins for primary prevention of CVD (40 years and over) (IND183)

    This indicator covers the percentage of patients with diabetes aged 40 years and over, with no history of cardiovascular disease and without moderate or severe frailty, who are currently treated with a statin (excluding patients with type 2 diabetes and a cardiovascular disease risk score of less than 10% recorded in the preceding 3 years). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM162

  11. NICE impact cardiovascular disease prevention

    Find out more about the progress made in implementing NICE guidance on cardiovascular disease prevention

  12. Press and media

    Information for journalists including contact details, FAQS and NICE's stance on key topics.

  13. Atrial fibrillation: diagnosis and management (NG196)

    This guideline covers diagnosing and managing atrial fibrillation in adults. It includes guidance on providing the best care and treatment for people with atrial fibrillation, including assessing and managing risks of stroke and bleeding.

  14. What is the improvement in the cost-effectiveness metrics for statin therapy in reducing CVD that can be obtained when using a complete individual patient-based outcomes meta-analysis data set compared with using published outcomes data?

    Question What is the improvement in the cost-effectiveness metrics for statin therapy in reducing CVD that can be obtained when using a...

  15. Stable angina: management (CG126)

    This guideline covers managing stable angina in people aged 18 and over. It outlines the importance of addressing the person’s concerns about stable angina and the roles of medical therapy and revascularisation.